RCUS Covered Call Strategy
RCUS (Arcus Biosciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
RCUS (Arcus Biosciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.64B, a beta of 0.81 versus the broader market, a 52-week range of 9.73-31.735, average daily share volume of 1.3M, a public-listing history dating back to 2018, approximately 601 full-time employees. These structural characteristics shape how RCUS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.81 places RCUS roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a covered call on RCUS?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
RCUS snapshot
As of August 14, 2026, spot at $29.41, ATM IV 70.10%, IV rank 39.38%, expected move 20.10%. The covered call on RCUS below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this covered call structure on RCUS specifically: RCUS IV at 70.10% is mid-range versus its 1-year history, so the credit collected on a RCUS covered call sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 20.10% (roughly $5.91 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RCUS expiries trade a higher absolute premium for lower per-day decay. Position sizing on RCUS should anchor to the underlying notional of $29.41 per share and to the trader's directional view on RCUS stock.
RCUS covered call setup
The RCUS covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RCUS at $29.41 on that close, the first option leg uses a $30.88 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RCUS chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RCUS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $29.41 | long |
| Sell 1 | Call | $30.88 | N/A |
RCUS covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
RCUS covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on RCUS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on RCUS
Covered calls on RCUS are an income strategy run on existing RCUS stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
RCUS thesis for this covered call
The market-implied 1-standard-deviation range for RCUS extends from approximately $23.50 on the downside to $35.32 on the upside. A RCUS covered call collects premium on an existing long RCUS position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether RCUS will breach that level within the expiration window. Current RCUS IV rank near 39.38% is mid-range against its 1-year distribution, so the IV signal is neutral; the covered call thesis on RCUS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RCUS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RCUS-specific events.
RCUS covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RCUS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RCUS alongside the broader basket even when RCUS-specific fundamentals are unchanged. Short-premium structures like a covered call on RCUS carry tail risk when realized volatility exceeds the implied move; review historical RCUS earnings reactions and macro stress periods before sizing. Always rebuild the position from current RCUS chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on RCUS?
- A covered call on RCUS is the covered call strategy applied to RCUS (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With RCUS stock at $29.41 on the most recent close, the strikes shown on this page are snapped to the nearest listed RCUS chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are RCUS covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the RCUS covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 70.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RCUS covered call?
- The breakeven for the RCUS covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The RCUS market-implied 1-standard-deviation expected move in the same options snapshot is approximately 20.10%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on RCUS?
- Covered calls on RCUS are an income strategy run on existing RCUS stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current RCUS implied volatility affect this covered call?
- RCUS ATM IV is at 70.10% with IV rank near 39.38%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.